Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.70 |
| ▸ | MALT1 | Q9UDY8 | 8/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.60 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | CA1 | P00915 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 1/20 | 0.58 |
| ▸ | CA9 | Q16790 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL213633 | 0.82 | PTGS2 (1.00) | PTGS2CHRNA7PTGS1CA1CA2 | |
| SCHEMBL6307479 | 0.82 | PTGS2 (0.77) | PTGS2CHRNA7SMN1; SMN2PTGS1CA1 | |
| SCHEMBL6013937 | 0.81 | PTGS2 (0.80) | PTGS2CHRNA7SMN1; SMN2PTGS1CA1 | |
| SCHEMBL27457917 | 0.80 | PTGS2 (0.78) | PTGS2CHRNA7SMN1; SMN2PTGS1CA1 | |
| SCHEMBL6013905 | 0.80 | PTGS2 (0.78) | PTGS2CHRNA7SMN1; SMN2PTGS1CA1 | |
| SCHEMBL6352494 | 0.80 | PTGS2 (0.74) | PTGS2MALT1EPHX2CHRNA7SMN1; SMN2 | |
| SCHEMBL6501484 | 0.80 | PTGS2 (0.74) | PTGS2EPHX2CHRNA7SMN1; SMN2PTGS1 | |
| SCHEMBL6343962 | 0.79 | CA9 (0.71) | PTGS2MALT1EPHX2PTGS1CA1 | |
| SCHEMBL20702138 | 0.78 | PTGS2 (0.75) | PTGS2CHRNA7SMN1; SMN2PTGS1CA1 | |
| SCHEMBL6309308 | 0.78 | PTGS2 (0.71) | PTGS2MALT1CHRNA7SMN1; SMN2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | PHARMACIA CORPORATION | 2003-06-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030119886-A1 | Heterocyclo substituted hydroxamic acid derivatives as cyclooxygenase-2 and 5-lipoxygenase inhibitors | ALOX5, ALOX12, ALOX15 | PTGS2 7/4885MALT1 1643/4885EPHX2 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.